Last $74.05 USD
Change Today 0.00 / 0.00%
Volume 0.0
AZNCF On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 8:10 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZNCF) Snapshot

Open
$74.05
Previous Close
$74.05
Day High
$74.05
Day Low
$74.05
52 Week High
05/1/14 - $81.70
52 Week Low
10/10/13 - $49.90
Market Cap
93.5B
Average Volume 10 Days
189.1
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
08/13/14
P/E TM
--
Dividend
$3.11
Dividend Yield
4.16%
Current Stock Chart for ASTRAZENECA PLC (AZNCF)

astrazeneca plc (AZNCF) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; Qiagen N.V.; and Illumina, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

51,500 Employees
Last Reported Date: 03/20/14
Founded in 1992

astrazeneca plc (AZNCF) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (AZNCF) Key Developments

US FDA Approves Astrazeneca's Opioid-Induced Constipation Drug Movantik

The US FDA has issued approval for AstraZeneca's Movantik (naloxegol) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. The decision was based on data from the KODIAC clinical programme, which included four studies: KODIAC-4, -5, -7, and -8. The company intends to make the drug available in the first half of next year. The company further noted that Movantik is a schedule II controlled substance at the moment due to its structural relationship to noroxymorphone. However, a petition was submitted by the company in 2012 to the US Drug Enforcement Administration for its descheduling, and was accepted for DEA review.

AstraZeneca Receives US Food and Drug Administration for MOVANTIK (Naloxegol) Tablets C-II

AstraZeneca announced that the US Food and Drug Administration (FDA) approved MOVANTIK™ (naloxegol) tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. Opioids play an important role in chronic pain relief and millions of patients are treated with them in the United States each year. They work by binding to mu-receptors in the central nervous system, but they also bind to mu-receptors in the gastrointestinal tract, which can result in patients suffering from OIC. The FDA approval of MOVANTIK was based on data from the KODIAC clinical programme, which is comprised of four studies: KODIAC-4, -5, -7 and -8. KODIAC-4 and -5 were both placebo controlled, double-blind, 12 week studies assessing safety and efficacy, while KODIAC-7 was a 12 week safety extension to KODIAC-4, and KODIAC-8 was a 52 week open label, long-term safety study. MOVANTIK is expected to be available to patients in the first half of 2015. MOVANTIK is currently a schedule II controlled substance because it is structurally related to noroxymorphone. During the review of the New Drug Application, the FDA evaluated the abuse potential of MOVANTIK and the approved labelling indicates that MOVANTIK has no risk of abuse or dependency. AstraZeneca submitted a petition for the descheduling of MOVANTIK to the US Drug Enforcement Administration (DEA) in March 2012, which was accepted for review and will be considered by the DEA as part of the process for addressing the descheduling request. Results from KODIAC-4 and -5 were published in the New England Journal of Medicine on 19 June 2014. Naloxegol is also under regulatory review by the European Medicines Agency (EMA).

AstraZeneca plc and Eli Lilly and Co. Reach Deal on BACE Inhibitor AZD3293 for Alzheimer's Disease

AstraZeneca plc and Eli Lilly and Co. announced that they reached a deal to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme or BACE inhibitor currently in development as a potential treatment for Alzheimer's disease. As per the terms of the deal, Lilly will pay AstraZeneca up to $500 million in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50 million in the first half of 2015. The companies will share all future costs equally for the development and commercialisation of AZD3293, as well as net global revenues post-launch. AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer's disease. Lilly will lead clinical development, working with researchers from AstraZeneca's Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialisation of AZD3293.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZNCF:US $74.05 USD 0.00

AZNCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $59.21 USD -0.2422
Bayer AG €112.16 EUR +0.153
Celgene Corp $93.75 USD +0.478
GlaxoSmithKline PLC 1,449 GBp +12.50
Novo Nordisk A/S kr281.70 DKK +0.10
View Industry Companies
 

Industry Analysis

AZNCF

Industry Average

Valuation AZNCF Industry Range
Price/Earnings 46.3x
Price/Sales 3.6x
Price/Book 4.3x
Price/Cash Flow 46.5x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.